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Abstract
Biologic agents that act by inhibiting tumour necrosis factor alpha (TNF-alpha) have 
become a breakthrough treatment for chronic inflammatory diseases. This highly effective 
treatment has surprisingly brought us new adverse effects that we had not encountered 
before the age of biologics. Immune-mediated reactions are a group of adverse effects 
with not clearly understood etiopathogenesis. It turns out that TNF-alpha inhibitors are 
able to disrupt the cytokine cascade in genetically predisposed individuals. Some of the 
theories assume a cross reaction and overproduction of interferon (INF) alpha, while 
others put an emphasis on dysregulation of cytokines, in particular interleukin (IL)-17. 
Similarly, debatable is the role of the reactions mentioned in the etiopathogenesis, the pro-
duction of antibodies against biologics and the production of antinuclear antibodies. The 
most common immune-mediated skin reactions are psoriasis and psoriasiform reactions, 
lupus-like syndrome, sarcoidosis, alopecia areata, vasculitis and lichenoid reactions. Less 
common reactions described in our paper include pyoderma gangrenosum and morphea. 
Most of these reactions belong to the so-called paradoxical reactions. Paradoxical psoria-
sis is an adverse effect, represented by occurrence of a disease caused by the therapeutic 
class of drugs normally used to cure or improve symptoms of such disease.
Keywords: TNF-alpha inhibitors, psoriasiform reaction, paradoxical reaction, 
antibodies, Th17
1. Introduction
Immune-mediated adverse reactions are a new group of diseases developing during anti-TNF-
alpha treatment. Their clear etiopathogenesis is not known. Most authors assume that there 
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is a link to possible significant interference of the anti-TNF-alpha therapy with the immune 
system, which subsequently induces the above-mentioned responses. Others associate the dis-
eases with the production of antibodies against the biologic agents and include the symptoms 
among hypersensitivity reactions. However, the individual genetic predisposition, which may 
be essential in detecting of immune-mediated reactions, must not be overlooked. The reac-
tions include a broad variety of diseases such as lupus-like syndrome, autoimmune arthralgia, 
psoriasis, sarcoidosis, dermatomyositis, hepatitis, vasculitis, neurological demyelinating dis-
eases and the like. In this chapter, we will briefly characterise the most common skin immune-
mediated reactions induced by TNF-alpha inhibitors.
TNF is produced as a transmembrane protein (tmTNF), which is later cleaved by an enzyme 
metalloproteinase to its soluble form, sTNF [1]. Both TNFR1 and TNFR2 receptors sig-
nal through pathways that are proinflammatory and anti-apoptotic. Moreover, TNFR1 can 
signal directly through death domain caspase-dependent pathways that lead to apoptosis 
[2]. TNFR1 plays a role in response to bacterial infection [3] and TNFR2 may downregulate 
inflammatory signals driven by TNF [4].
Currently, five complete recombinant antibodies—infliximab, etanercept, adalimumab, goli-
mumab and certolizumab pegol—are available TNF-α inhibitors. They are biotechnologically 
produced and administered as systemic drugs modifying the biological response and signali-
sation on the molecular level. The structural differences are key to different risk for adverse 
effects such as granulomatous infections, with TNF antibodies associated with higher risk com-
pared to soluble receptor, possibly due to binding to tmTNF receptor on the activated cells [5].
Infliximab is a recombinant chimeric monoclonal antibody containing human IgG1 Fc and 
variable murine regions, which forms complexes with both sTNF and tmTNF. It induces the 
lysis of macrophages and monocytes by cytotoxicity dependent on complement and anti-
bodies [6]. The intravenous administration is applied by a weight-dependent dose. Drug-
mediated apoptosis and monocytopenia are linked to infliximab as well as its ability to bind 
more avidly to different forms of TNF-α [7]. Adalimumab is a humanised monoclonal antibody 
containing human IgG1 Fc and human variable regions that bind sTNF as well as tmTNF. The 
other available humanised monoclonal antibody, cetrolizumab pegol is a pegylated monoclo-
nal Fab fragment with polyethylene glycol binding to soluble and membrane-bound TNF-α, 
inhibiting the proinflammatory actions of this cytokine. Unlike other TNF inhibitors, owing 
to its lack of the Fc component, it is incapable of fixing complement or binding to Fc receptors. 
Golimumab is a human anti-TNF monoclonal antibody containing the IgG1 constant region.
The other group of TNF inhibitors consists solely of etanercept, which is soluble TNF receptor 
containing the human IgG1 Fc portion fused to the extracellular portion of human TNFRp75. 
It creates less stable complexes with tmTNF and firmly binds to trimeric forms of soluble TNF.
2. Psoriasis
TNF-alpha inhibitors have become a revolutionary medication in the treatment of chronic pso-
riasis in recent years. Conversely, psoriasis or psoriasiform reaction is one of the most common 
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immune-mediated reactions. Therefore, the formation of TNF alpha-induced psoriasis is also 
called a paradoxical reaction. All of the mentioned TNF-alpha antagonists can induce psoriasis. 
Cases have been reported from all indications where anti-TNF-alpha treatment is given. According 
to the literature, the incidence of paradoxical psoriasis is 1.04–3.0 cases per 1000 patient-years, the 
percentages varying widely from 0.6 to 5.3% [8]. The incidence of the manifestation is not age and 
gender related; some studies also show other controversial data. Manifestation may occur in any 
period of time during the treatment, from weeks, months, up to the years. The average time of 
developing psoriasis is 10 months [9, 10]. Concomitant treatment with another immunosuppres-
sant does not appear to prevent paradoxical psoriasis, although combined suppression is used in 
the treatment of immune-mediated reactions.
The clinical manifestation of paradoxical psoriasis may be variable in nature. Paradoxical pso-
riasis includes not only newly developed psoriasis but also a radical worsening of already 
existing psoriasis. The disease is most commonly manifested in the area of palms and soles 
in the form of palmoplantar pustulosis, which is reported in 56% of cases, other most com-
mon forms include chronic plaque psoriasis in 50% of the patients and guttate manifestations, 
which affect 12% of the patients. Patients may also suffer from multiple forms of disease 
simultaneously (15%) [11]. Other manifestations include scalp or nail involvement. There are 
also cases of alopecia areata and paradoxical psoriasis. Some authors assume that monoclonal 
antibodies are associated with development of de novo-induced psoriasis, while the etaner-
cept fusion protein causes a worsening of pre-existing psoriasis [12] (Figure 1).
The exact etiopathogenesis of paradoxical psoriasis is not clear, and there are several opinions 
and theories. The first of them states that the manifestations are a hypersensitive reaction to a 
drug, not a newly developed classical disease. There are papers that due to the increased pro-
duction of antibodies against biologics describe manifestations of induced generalised pus-
tulosis that could fit into the spectrum of hypersensitivity reactions. Other papers disprove 
this theory on the basis of skin biopsy of the patients with TNF-alpha-induced psoriasis. The 
incidence of palmoplantar pustulous psoriasis in the common psoriatic population is signifi-
cantly lower, representing 1.7% compared to 46.2% in patients with paradoxical reaction. This 
fact supports the theory that it should not be a new classical form of psoriasis [13].
The most widespread theory links the relationship between TNF-alpha and type 1 interferon 
alpha. TNF-alpha inhibits the maturation of plasma dendritic cells that produce IFN-alpha. 
Figure 1. Patient with severe palmoplantar pustular psoriasis induced after 4 weeks of using adalimumab, this severe 
reaction lead to discontinuation of adalimumab.
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The central role of INF-alpha in the etiopathogenesis of paradoxical psoriasiform reaction con-
sists of cross-regulation between TNF-alpha and IFN-alpha. TNF-alpha blockers can lead to 
overproduction of INF-alpha. In papers that confirm this theory, increased expression of inter-
feron alpha was demonstrated in skin biopsy compared to common psoriatic findings [14]. It 
is also believed that the expression of CXCL9 and CXCR3 chemokine receptors is increased, 
which promote the migration of lymphocytes into psoriatic dermis resulting in skin damage. 
IFN-alpha induces the expression of chemokine receptors on T lymphocytes [15].
One of the latest theories involves the Th17 pathway. In recent years, the Th17 signalling 
pathway is considered to be the major pathway of psoriasis etiopathogenesis. TNF-alpha 
may cause dysregulation in the immune system, which may cause the following changes. 
Activation of the IL-12/IL-23 pathway activates the Th17 signalling pathway followed by the 
production of IL-1b, IL-17, IL-21 and IL-22 together with an increased production of IL-17A 
and IL-22, hyperactivation of the Th17 and Th1 pathway and reduction of Treg activity [8, 15].
The genetic predisposition in patients with paradoxical reactions is not fully elucidated. 
Comorbidities are diseases that occur simultaneously with primary disease in higher prev-
alence compared to general population. Psoriasis comorbidities include a large group of 
diseases that are treated with anti-TNF-alpha therapies. It is believed that the genetic predis-
position of an individual should also be essential for the development of immune-mediated 
reactions. There is a large group of “susceptibility” genes that are characteristic of several 
diseases and encode common inflammatory pathways. Polymorphisms of these genes are the 
subject of scientific research. Cabaleiro et al. presented the first paper studying 25 patients 
who developed paradoxical psoriasis genotyped for 173 single-nucleotide polymorphisms 
(SNPs) using the Illumina Veracode genotyping platform. Multivariate logistic regression 
revealed that five SNPs (rs11209026 in IL23R, rs10782001 in FBXL19, rs3087243 in CTLA4, 
rs651630 in SLC12A8 and rs1800453 in TAP1) were associated with paradoxical reactions [16].
Recently, we presented a study where we analysed antinuclear antibodies (ANA) and anti-dou-
ble stranded DNA (dsDNA) antibodies in 10 patients with anti-TNF-alpha treatment induced 
psoriasis. ANA and anti-dsDNA antibodies were detected by ELISA. ANA serum samples 
were positive in 10% patients and anti-dsDNA antibody samples in 70% patients. The mecha-
nism driving the formation of ANA and anti-dsDNA antibodies is poorly understood and their 
clinical significance is unknown [17]. In the literature, the frequency of ANA and anti-dsDNA 
antibodies in the patients after anti-TNF-alpha treatment varies extremely, possibly due to dif-
ferent methods of detection used. Pink et al. in their study, suggest that the development of 
ANA and anti-dsDNA antibodies on anti-TNF treatment may act as a marker of forthcom-
ing treatment failure. In anti-TNF-alpha-induced lupus erythematosus, ANA and anti-dsDNA 
antibodies are well established and quite common (ANA, 90%; anti-dsDNA, 70–90%), but we 
have limited data about other immunological mediated adverse reactions [18]. Our data sug-
gest that paradoxical psoriasis induced by anti-TNF inhibitors is associated with production of 
anti-dsDNA autoantibodies, but not with production of ANA antibodies. Further prospective 
research is necessary before general recommendations for daily practice can be announced. 
Genetic predisposition, clinical manifestation and production of anti-dsDNA antibodies seem 
to be fundamental in differentiation between adverse effects of anti-TNF-alpha treatment and 
associated disease comorbidity.
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The therapeutic approach for anti-TNF-alpha-induced psoriasis is individual in each patient. 
A very important factor is the condition of the underlying disease, for which the treatment 
was indicated. In case of a serious condition that was stabilised with the treatment, we try 
to keep the biologic agent as long as possible. Equally important is what other therapeutic 
options are available. While in rheumatology we have a wide variety of biological medica-
tions for most diseases, including some others than anti-TNF-alpha inhibitors, the situation in 
patients with inflammatory bowel diseases (IBD) is much more complex.
Literature sources mention the following procedures: if the skin psoriatic manifestations 
involve up to 5% of the body surface, the first-line therapy should be topical (corticosteroid 
therapy, keratolytic therapy, treatment with vitamin D derivatives) followed by phototherapy 
and, in case of resistance, introducing methotrexate to the patient’s therapy. In case that more 
than 5% of the body surface is involved, the recommended first-line therapy consists of topi-
cal corticosteroids and phototherapy, followed by methotrexate, cyclosporine and retinoids 
[11]. When setting up the combined suppression, the patient’s comorbidities are very impor-
tant. Most patients with underlying rheumatologic disease were treated with methotrexate 
in the past. For IBD patients, it is important to use the injection form of methotrexate, oth-
erwise the drug may not be resorbed. In case of refractory manifestations and contraindica-
tions of combined systemic therapy, we consider discontinuing the anti-TNF-alpha agent. 
Interdisciplinary cooperation, consideration of the underlying disease and reassessment of 
further therapeutic procedure are all very important.
3. Sarcoidosis
One of the so-called paradoxical reactions is also newly developed sarcoidosis during the 
anti-TNF-alpha therapy. The anti-TNF-alpha therapy was described as a possible success-
ful therapeutic modality in severe sarcoidosis manifestations. On the other hand, there is a 
growing number of cases that are caused by the treatment. More than 50 cases of TNF-alpha-
induced sarcoidosis have been reported in the literature. Treatment with etanercept induced 
nearly 2/3 of the cases, and others were caused equally by infliximab and adalimumab. In 
most patients, the symptoms appeared after several months (1–69). Concomitant diseases 
include rheumatoid arthritis (in 60%), ankylosing spondylitis (in 20%), as well as psoriasis, 
Juvenile idiopathic arthritis (JIA) and IBD. In the clinical picture of anti-TNF-alpha-induced 
sarcoidosis, the pulmonary and cutaneous forms of the disease were dominant. In an aggre-
gate paper including 38 patients, 74% of the patients suffered from the pulmonary form and 
29% from the skin manifestations. The skin symptoms were manifested as erythema nodo-
sum, pigmented scars and nodular lesions [19]. Literature data indicate a possible occurrence 
of sarcoidosis in 0.04% of the patients treated with TNF-alpha inhibitors [20]. Differential 
diagnosis of symptoms along with histological examination is important.
The role of anti-TNF on granuloma [21] and the different behaviour of antibodies and soluble 
anti-TNF alpha receptor in granulomatous diseases, with a greater tendency of etanercept 
to induce granulomatous reactions, may account for the occurrence of lesions. Monoclonal 
antibodies may induce apoptosis in activated monocytes and T cells. Sarcoidosis-like lesions 
Immune-Mediated Skin Reactions Induced by Recombinant Antibodies and Other TNF-Alpha…
http://dx.doi.org/10.5772/intechopen.72449
263
may develop during the anti-TNF-alpha treatment. The anti-TNF-alpha treatment increases 
the IL-17 and IFN-ϒ expression and disturbs the balance between Th17 and Treg in favour of 
Th17. These two factors may result in the development of sarcoidosis [22].
4. Lupus-like syndrome
Systemic lupus erythematosus (SLE) is a common autoimmune disease, with 10% of SLE 
cases being drug-induced. The autoimmune drug-induced response is idiosyncratic, influ-
enced by multiple factors, such as genetics, comorbidities, interactions with other medicinal 
products and external environmental factors [23]. Drug-induced lupus erythematosus (DILE) 
is defined as a lupus-like disease that is temporally related to drug exposure (from 1 month 
after the commencement of drug application but sometimes even more than 10 years) [24].
DILE may not meet all the SLE criteria. The most common manifestations are arthritis, serosi-
tis, the presence of ANA antibodies and anti-histone antibodies. The most important criterion 
is that the symptoms cease after discontinuing application of the suspected drug [25].
DILE induced by TNF-alpha inhibitors appears to be a separate DILE group with different 
signs compared to classical DILE. Women are more often affected than men, with an aver-
age age between 46.2 and 50.9 years. The average time to the manifestation of symptoms 
is 40.6 weeks from the commencement of drug treatment. Skin manifestations occur more 
frequently than in classical DILE and include butterfly erythema, photosensitivity and other 
skin manifestations of systemic and sub-acute lupus. The exact mechanism of DILE formation 
during anti-TNF-alpha treatment is unknown. Post-marketing follow-ups have demonstrated 
that DILE induced by TNF-alpha inhibitors may occur across all anti-TNF-alpha inhibitors. 
However, it is more often reported with the use of infliximab (0.19–0.22%) and etanercept 
(0.18%) compared to adalimumab (0.10%). An increase in ANA or anti-DNA antibodies in 
patients treated with anti-TNF-alpha therapy is known and relatively common [26]. The fre-
quency of elevated ANA antibodies was higher in a greater number of patients treated with 
infliximab compared to a group of patients treated with etanercept [27]. Anti-dsDNA anti-
bodies as well as ENAs (extractable nuclear antibodies) and low complement levels have been 
described more often than in case of classical DILE. Particularly, anti-histone antibodies have 
been more common in DILE induced by anti-TNF-alpha treatment [28, 29] (Figure 2).
The basic therapeutic procedure is the discontinuation of the treatment with the drug that 
induced the symptoms. In more severe conditions, it is necessary to add suppressors—cor-
ticosteroids, azathioprine, cyclosporine and methotrexate. Treatment selection is also based 
on the status of the underlying disease and comorbidities of the patient. In psoriasis, it is 
recommended to avoid systemic corticosteroids for a possible rebound phenomenon after 
discontinuation. There is no need to discontinue the treatment of anti-TNF-alpha in the case 
of ANA positivity or in very mild DILE manifestations [26]. Only limited data are available 
in the literature describing a switch of the treatment to another anti-TNF-alpha agent. Some 
authors claim that a similar reaction can be caused by any of the agents from the group of anti-
TNF-alpha inhibitors [30]. As stated by Lomicova et al., an alternative treatment for chronic 
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plaque psoriasis is ustekinumab. Ustekinumab is also a good alternative in the treatment of 
inflammatory bowel disease and in the treatment of spondylarthritis or psoriatic arthritis [31]. 
However, the literature contains also cases of an ustekinumab-induced DILE. Biologics with a 
different mechanism of action are alternative treatments, but it cannot be said whether other 
mechanisms of action (anti-IL13/23, anti-IL-17, anti-IL 6) will be a potential threat to DILE 
induction in genetically predisposed individuals.
5. Vasculitis
The manifestations of vasculitis are another disease that is associated with the anti-TNF-alpha 
treatment. Several case reports and patient groups have been described in the literature. In 
almost half of the cases, leukocytoclastic vasculitis was histologically described, while the 
other patients included cases of necrotising vasculitis, lymphocytic vasculitis and urticarial 
vasculitis [32].
An aggregate paper of 118 cases of vasculitis newly formed during the anti-TNF-alpha treat-
ment (99 cases of rheumatoid arthritis, 8 Crohn’s disease, 5 juvenile rheumatoid arthritis, 
3 ankylosing spondylitis, 3 psoriasis) presented skin manifestations in 86% of patients. The 
anti-TNF agent administered was etanercept in 60 (51%) cases, infliximab in 51 (43%), adali-
mumab in 5 (4%) and other agents in 2 (2%). Purpura was manifested in 63% of the patients, 
whereas others had other skin manifestations of vasculitis, such as ulcerations, nodosities, 
maculopapular manifestations, etc. Systemic involvement was observed in 24% of patients. 
Immunological examinations showed that the antinuclear antibodies (ANAs) were positive 
in 27 patients and antineutrophil cytoplasmic antibodies (ANCAs) in 11 patients (pANCA in 
5 patients and cANCA in 1 patient). Treatment in the form of anti-TNF-alpha discontinua-
tion was used in 11 patients, 71 of whom completely recovered (41% of them had additional 
immunosuppressive therapy) [33]. Mohan et al. describe in an aggregate paper including 50 
patients that almost 63% of patients experienced a complete recovery of the manifestations 
after discontinuation of the anti-TNF-alpha treatment [34].
Figure 2. Significant facial erythema, total weakness and laboratory elevated ANA antibodies were observed. After 
discontinuation of the treatment, gradual regression of skin manifestations and neutralisation of ANA antibodies took 
place. Manifestations were assessed as DILE after infliximab.
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Vasculitis manifestations in patients with severe seropositive rheumatoid arthritis are debat-
able, because the manifestations may be evaluated as rheumatic vasculitis, which is an extra-
articular manifestation of rheumatoid arthritis and not drug-induced vasculitis. In such cases, 
some authors recommend discontinuation of the anti-TNF-alpha treatment with possible re-
exposure to the given treatment [32]. The same situation applies also to patients with IBD, 
where leukocytoclastic vasculitis can be associated with the disease itself [35].
The pathogenesis of vasculitis associated with anti-TNF treatment is not completely explained. 
An immune complex-mediated hypersensitivity vasculitis may be related to the development 
of antibodies against anti-TNF agents, but in this hypothesis, the cases with etanercept should 
be less frequent since the treatment with the soluble receptor induces less antibody forma-
tion than monoclonal antibodies. Overexpression of type I interferon secondary to imbalance 
between Th1 and Th2 cytokine production under TNF inhibition may favour induction of 
autoimmune disorders such as vasculitis [15].
6. Pyoderma gangrenosum
Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis. PG is manifested by severe pain-
ful non-infectious pustules, nodules and necrotising ulcerations. The defects are sharply demar-
cated, round, with distinctly dark red undermined edges. The manifestations occur mostly on 
the shins, but they can also be found on the torso and other body parts. The manifestations of 
PG can be divided into several clinical forms, namely pustulous, bullous, a vegetative form of 
the disease and a separate peristomic form [36]. The peristomic form is a sign of pyoderma gan-
grenosum with pathergy; any trauma and injury of skin cover can cause new manifestations of 
the disease. The peristomic form may develop from 2 weeks to 3 years after the initial creation of 
the stoma [37]. Key factors in the etiopathogenesis of the disease are IL1B, IL-17, TNF-alpha and 
other chemokines that activate neutrophils for their activity. Genetic examinations point to sev-
eral autoinflammatory genes, including pyrin innate immunity regulator (MEFV) and proline-
serine-threonine phosphatase interacting protein-1 (PSTPIP1) [38]. About 50% of PG cases are 
associated with underlying diseases, such as inflammatory bowel disease, rheumatoid arthritis, 
myelodysplastic syndrome and haematological malignancies [39, 40]. Several papers indicate 
that refractory forms of PG are well responsive to the treatment with TNF-alpha inhibitors. 
One of the latest summary papers on drug-induced manifestations of pyoderma gangrenosum 
describes five case reports of pyoderma gangrenosum induced by an anti-TNF-alpha therapy. 
Three patients had manifestations induced by infliximab, one case of PG was induced by etan-
ercept and one by adalimumab. Etiopathogenesis of PG induced by TNF-alpha inhibitors may 
represent paradoxical reaction due to a shift towards Th-17 polarisation [41].
7. Alopecia areata
Pathogenesis of alopecia areata is associated with TNF-alpha, which, as demonstrated in in vitro 
studies, inhibits hair follicle growth. However, in clinical trials with etanercept, the efficacy of 
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anti-TNF-alpha therapy for the alopecia areata was not confirmed. In the literature, however, 
there are cases of newly developed manifestations of alopecia areata, total and universal alope-
cia during anti-TNF-alpha treatment [42, 43].
French authors present data from a multicentre prospective study of patients who received 
anti-TNF-alpha treatment due to dermatological (11 patients), rheumatological (11 patients) 
and gastroenterological indications (7 patients). From these patients, 10 were treated with inf-
liximab, 11 with adalimumab and the following 8 with etanercept. In the population, a total of 
29 patients were diagnosed with alopecia areata, which was confirmed by a dermatologist. The 
manifestations of alopecia areata were in the area of scalp and chin in 79% of the patients. There 
were interesting findings related to concomitantly associated immune-mediated diseases, 
namely the occurrence of vitiligo, psoriasis or psoriasis-like manifestations and autoimmune 
thyroiditis. In the study group, nine patients had a positive family history of alopecia areata 
or vitiligo. A total of 14 patients discontinued the anti-TNF-alpha treatment and 15 patients 
continued the treatment. From patients who discontinued treatment, four were treated with 
infliximab, six with adalimumab and four with etanercept. Improvement up to complete disap-
pearance of the symptoms was observed in 76% of the patients, while there was no difference 
between the groups in which the treatment discontinued or continued [44] (Figure 3).
Etiopathogenesis of alopecia areata is not clear. Some authors explain the occurrence of alope-
cia areata similar to TNF-alpha-induced psoriasis. Inhibition of TNF-alpha results in dysregu-
lation of cytokines and subsequent production of IFN-alpha, which results in a pathological 
process [43]. However, further research is needed to better understand the occurrence of alo-
pecia areata during anti-TNF-alpha therapy.
8. Lichen ruber planus and lichen planus-like reaction
Several cases of lichen planus and lichen planus-like paradoxically incurred lesions induced 
by anti-TNF-alpha therapy were reported in the literature. The manifestations have different 
clinical variability, including mucosal signs, but histologically they have signs of lichen planus.
The clear cause of lichenoid reactions in the treatment of anti-TNF-alpha is not known. Lichen 
is T-cells and dendritic cells mediated dermatosis. As with other immune-mediated diseases, 
Figure 3. Adalimumab induced alopecia areata, spontaneous complete disappearance of the symptoms after 10 months 
without the drug discontinuation.
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pro-inflammatory cytokines and TNF-alpha play a key role [45]. Studies point to increased 
TNF-alpha levels in saliva and plasma in the patients with lichen planus [46, 47]. Papers 
indicating good therapeutic effect of TNF-alpha inhibitors on lichenoid lesions were also 
published. Some authors describe a similar theory of etiopathogenesis of lichen planus as in 
paradoxical psoriasis. As we have already mentioned in case of other immune-mediated reac-
tions, the model in which anti-TNF-alpha induces IFN-alpha may also be valid for lichen and 
lichenoid reactions. Other studies indicate that type 1 IFN including IFN-alpha can induce 
lichen planus through the activation of cytotoxic CD8 + T cells [45].
9. Morphea-like reactions
Morphea, also called localised scleroderma, is manifested by thickening of the skin and sub-
cutaneous tissue due to the deposition of excessive amounts of collagen. There are only a few 
cases of morphea induced by TNF-alpha reported in the literature. Morphea may be induced 
by mechanical effects or by medications. The exact etiopathogenesis of TNF-alpha-induced 
morphea is not known, although there are several theories of possible etiopathogenesis. TNF 
inhibitors can act on tumour growth factor beta (TGF beta 1), a profibrotic cytokine that effects 
the growth and accumulation of extracellular matrix by the action of fibroblasts and endothe-
lial cells. An increase in Th1 and Th17 proinflammatory cytokines has been demonstrated in 
the early stage of localised scleroderma. Th2 lymphocytes correlate with the severity of the 
disease and the extent of fibrosis. Inhibition of Th1 response induced by TNF-alpha inhibitors 
may lead to the prevalence of Th2 lymphocytes, which may be the cause of morphea [48].
10. Vitiligo
Vitiligo is one of the other rare skin disorders that can occur with anti-TNF-alpha treatment. The 
role of anti-TNF-alpha inhibition in the development of vitiligo is complex and controversial. 
As with other paradoxical immune-mediated reactions, there are case studies where vitiligo 
has been significantly improved in anti-TNF-alpha therapy in vitiligo patients. The therapeutic 
effect of anti-TNF-alpha treatment on vitiligo is believed to be blocking the physiological effect 
of TNF-alpha on melanogenesis. According to the literature, TNF-alpha reduces tyrosinase lev-
els. The melanocytic effect of TNF-alpha on vitiligo has also been demonstrated [49].
11. Other skin manifestations
Cases of newly developed dermatomyositis and polymyositis have been described in a num-
ber of papers. Most of the patients belonged to the group of patients treated for rheumatic 
disease. The authors predict a possible association between the presence of myositis-specific 
anti-Jo-1 autoantibodies and anti-TNF-alpha treatment in relation to newly developed derma-
tomyositis and polymyositis in patients with rheumatoid arthritis [50].
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12. Discussion
TNF-alpha inhibitors are biotechnologically produced medicinal products that differ from 
conventional drugs in their properties, size and structure. These large molecules, even with 
the same mechanism of action in the form of inhibiting TNF-alpha, may act differently and 
they may have other adverse effects. Therefore, each biological agent is unique. Pre-clinical 
studies did not foreseen that TNF-alpha inhibitors will disrupt and change immunological 
pathways. In 2004, the first case of TNF-alpha-induced psoriasis [51] was described, and since 
then a number of papers have been published with immune-mediated skin reactions induced 
by TNF-alpha inhibitors. Their clinical spectrum is still widening; although in some cases, 
there are just a few case reports worldwide. Paradoxical psoriasis is the most researched 
and most common skin immune-mediated adverse effect. Its exact etiopathogenesis is still 
unclear. Development in the area of psoriasis etiopathogenesis is significantly moving for-
ward; the Th17 pathway, which is now considered to be crucial, was discovered only a few 
years ago, and now we are using anti-IL17 inhibitors in clinical practice.
In conventional systemic therapy, the emergence of immune-mediated reactions is consid-
ered a comorbidity of the disease. Comorbidities are diseases that occur more frequently 
with the primary disease than in the general population [52]. It is assumed that the diseases 
have a common genetic predisposition that encodes certain inflammatory pathways. A very 
good example is the IL23 receptor gene, which explains the increased incidence of psoriasis in 
patients with ankylosing spondylitis, Crohn’s disease and ulcerative colitis [52]. The literature 
contains only very little data about gene polymorphisms in paradoxical psoriasis. One study 
of gene polymorphisms that might be responsible for the above-mentioned reactions was 
published in 2015 by Cabaleiro et al., who observed in a group of 161 patients with psoriasis 
that 25 patients experienced a change in the morphology of psoriasis and 88% of the patients 
in the group had guttate psoriasis [16]. From a clinical point of view, it is debatable whether 
the monitored group had a real paradoxical psoriasis or whether it was just a worsening of the 
clinical condition, which is manifested in guttate form. The definition of a paradoxical pso-
riasiform reaction is newly induced or markedly clinically worsened psoriasis. As mentioned 
earlier, Collmar et al. reported that the most common clinical manifestations were palmo-
plantar pustulosis and chronic plaque psoriasis. Guttate forms are found in only 12% of the 
patients [11]. The problem of determining whether it is an adverse effect or not is encountered 
also with other immune-mediated reactions.
Wang et al. highlight in their paper the importance of properly diagnosing the adverse effect. 
The Naranjo Adverse Drug Reaction Probability Scale is used for determining the adverse 
effects. Based on this scoring system, it is possible to calculate the likelihood if it is an adverse 
drug reaction or not [41]. A very difficult situation is when determining the adverse effects in 
patients with IBD. More than 40% of the patients with chronic inflammatory bowel disease 
have extraintestinal manifestations. They are more common in the case of Crohn’s disease (CD) 
than in patients with ulcerative colitis (UC). The most common manifestations are peripheral 
arthritis, aphthous stomatitis, uveitis and erythema nodosum and pyoderma gangrenosum. 
Skin is the most frequently affected organ in extraintestinal manifestations [53]. Therefore, if 
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the above-mentioned manifestations of anti-TNF-alpha treatment occur, we first need to think 
of possible extraintestinal manifestations. Erythema nodosum (EN) is the most common skin 
manifestation of IBD, affecting 4–15% of the patients with CD and 3–10% of the patients with 
UC. EN is a reactive manifestation and correlates with the severity of the intestinal disease; it 
is aggravated in the case of colitis attacks [54].
Conversely, erythema nodosum may also be the first manifestation of paradoxically induced 
sarcoidosis. Pyoderma gangrenosum is also problematic. Pyoderma gangrenosum (PG) is the 
second most common, most serious and most debilitating skin manifestation in IBD. Unlike 
EN, the manifestations are more frequent in UC (5–12%) than in CD (1–2%) [55]. As we have 
already stated, pyoderma gangrenosum may also be a paradoxical response to anti-TNF-
alpha treatment. The issue of comorbidity or paradoxical reaction is also in the case of vascu-
litis present in IBD, as well as with inflammatory rheumatic diseases. As we have stated in the 
previous section, only discontinuation of the biologically medicinal product and spontane-
ous disappearance of skin manifestations is evidence of the adverse drug reaction. Acquiring 
a unified view of immune-mediated adverse effects requires thorough pharmacovigilance, 
reporting of adverse effects, long-term monitoring of safety registry data and complement-
ing the polymorphism research. Each biological agent is original, and even the batches do 
not have to be absolutely identical. By introducing biological similar molecules (biosimilars), 
the situation can get even more complicated. The biosimilar does not need to have the same 
immunogenicity as the original molecule.
Today, we know that antibodies against biologic agents are more likely to play a role in drug 
efficacy and hypersensitivity reactions, but some of the theories of pathogenesis of immune-
mediated reactions are also associated with their production. An important fact is that there 
are cases where a number of immune-mediated reactions have occurred in one patient [44]. 
We assume that in susceptible individuals, each new biological agent may interfere with a 
new mechanism of action with natural physiological processes and induce still new immune-
mediated adverse effects. Therefore, there is a tendency to apply one biological agent as long 
as possible to prevent further intervention in the cytokine cascade. We also know that the 
clinical response to the second and other biological agent is weaker than in treatment-naive 
patients, and the production of antibodies against biological medicinal products is more pro-
nounced. The question of whether immune-mediated reactions are associated with the forma-
tion of antinuclear antibodies is also unclear. The literature describes cases of monitoring the 
efficacy of a biological medicinal product and the formation of antinuclear antibodies [17]. 
However, firm data have not yet been established; similarly, we only assume that some type 
of immune-mediated reactions may be associated with anti-dsDNA formation and lupus-like 
reactions may be induced by TNF-alpha treatment with the formation of ANA.
Our work draws attention to the issue of adverse effects that occur due to the disruption of 
natural mechanisms—by dysregulation of the immune system and by starting various inflam-
matory pathways in genetically susceptible individuals. Some of the above-mentioned reac-
tions have a common hypothesis of formation, such as the theory of interferon induction. 
This knowledge may lead to the assumption that one biological agent can cause two reactions 
simultaneously in one patient, e.g. alopecia areata and psoriasis.
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